Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison
Multi-Agent Collaborative Framework for Adverse Drug Reaction Prediction: Evidence-Based Verification and Human-Machine Decision Comparative Study
研究概览
地位
详细说明
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Weilong Zhang
- 电话号码:010-82266782
- 邮箱:zhangwl2012@126.com
学习地点
-
-
-
Beijing、中国
- 尚未招聘
- Peking University Third Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- 招聘中
- Peking University Third Hospital
-
接触:
- Hongmei Jing, Dr.
- 电话号码:010-82266782
- 邮箱:hongmeijing@bjmu.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
This study includes two types of research subjects:
Retrospective de-identified adverse drug reaction (ADR) medical records: A total of 253 ADR consultation cases covering anti-infectives, cardiovascular agents, anti-tumor drugs, central nervous system drugs and digestive system drugs. Each case contains complete medical history, medication records, ADR occurrence process and clinical outcome data, as well as at least one clinically confirmed definite ADR event.
Clinical evaluators: 20 licensed physicians or pharmacists holding intermediate or higher professional titles, with clinical pharmacy practice and regular participation in hospital ADR monitoring and consultation work.
描述
Inclusion Criteria:
- Cases shall involve drug categories including anti-infectives, cardiovascular agents, anti-tumor drugs, central nervous system drugs, digestive system drugs, etc. Each case must contain at least one definite adverse drug reaction (ADR) event, with complete supporting documentation (medical history, medication history, ADR occurrence process, and clinical outcome).
Exclusion Criteria:
- Cases with incomplete supporting documentation lacking medical history, medication history, ADR occurrence process or clinical outcome.
- Cases only with suspected or possible ADRs without definite clinical confirmation.
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Coverage rate of known ADRs
大体时间:Up to 8 weeks
|
Up to 8 weeks
|
|
Objective question accuracy
大体时间:Up to 24 weeks
|
Up to 24 weeks
|
|
Concordance rate of predicted unknown ADRs
大体时间:Up to 8 weeks
|
Up to 8 weeks
|
|
Expert-rated subjective answer quality
大体时间:Up to 24 weeks
|
Up to 24 weeks
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Subgroup differences in ADR recognition coverage rate
大体时间:Up to 24 weeks
|
Up to 24 weeks
|
|
Inter-rater consistency
大体时间:Up to 24 weeks
|
Up to 24 weeks
|
|
Subgroup differences in answer quality score
大体时间:Up to 24 weeks
|
Up to 24 weeks
|
|
Rater acceptance scale score
大体时间:Up to 24 weeks
|
Up to 24 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- LLSC-2026288
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.